// App-Quantinova.ai

TPS5606 : A randomized, double-blind phase 3 trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy.

Researchers

Presenter

  • Antonio Gonzalez-Martin

Principal Investigators

  • Klaus H. Baumann

  • Dana Meredith Chase

  • Mathias Konrad Fehr

  • Robert L. Coleman

  • Gilles Freyer

  • Paul DiSilvestro

  • Ofer Lavie

  • Thomas J. Herzog

  • Domenica Lorusso

  • Kathleen N. Moore

  • Mansoor Raza Mirza

  • Roisin Eilish O'Cearbhaill

  • Ignace Vergote

  • Bhavana Pothuri

  • John Balser

  • Shefali Agarwal

  • Bradley J. Monk

Medical Centers

  • GEICO & MD Anderson Cancer Center Madrid, Madrid, Spain

  • Ohio State University Wexner Medical Center, Columbus, OH

  • AGO & University in Marburg, Marburg, Germany

  • University of Arizona Cancer Center, Tucson, AZ

  • SAKK & Frauenfeld General Hospital, Frauenfeld, Switzerland

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • GINECO & Centre Hospitalier Lyon-Sud, Lyon, France

  • Women & Infants Hospital, Providence, RI

  • ISGO & Technion University, Haifa, Israel

  • University of Cincinnati, Cincinnati, OH

  • MITO/MaNGO & Fondazione IRCCS National Cancer Institute, Milan, Italy

  • University of Oklahoma Health Sciences Center, Oklahoma City, OK

  • NSGO & Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • BGOG & University of Leuven, Leuven, Belgium

  • New York University, New York, NY

  • Veristat, Inc., Holliston, MA

  • TESARO, Inc., Waltham, MA

Locations

  • Italy

  • Spain

  • Germany

  • Switzerland

  • United States

  • Israel

  • France

  • Denmark

  • Belgium

Companies

  • Veristat, Inc.

  • TESARO, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Ovarian cancer

  • Acute myelocytic leukemia

  • Peritoneal cancer

  • Gynaecological cancer

  • Solid malignancies

Biomarkers

  • Cancer antigen 125

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Niraparib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

Phase

  • III

Study Id's

  • NCT02655016

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved